Celgene cost-sharing deal sways NICE to greenlight new Revlimid use

Celgene ($CELG) used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on a new use for Revlimid. The U.S.-based drugmaker capped its cost. Could this sort of cost-sharing deal help payers wrangle with other pricey meds? Report